- Home
- BHLB vs ARQT Comparison
BHLB vs ARQT Comparison
Compare BHLB & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BHLB
- ARQT
- Stock Information
- Founded
- BHLB 1846
- ARQT 2016
- Country
- BHLB United States
- ARQT United States
- Employees
- BHLB N/A
- ARQT N/A
- Industry
- BHLB Banks
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- BHLB Finance
- ARQT Health Care
- Exchange
- BHLB Nasdaq
- ARQT Nasdaq
- Market Cap
- BHLB 1.3B
- ARQT 1.1B
- IPO Year
- BHLB 2000
- ARQT 2020
- Fundamental
- Price
- BHLB $28.49
- ARQT $12.68
- Analyst Decision
- BHLB Buy
- ARQT Strong Buy
- Analyst Count
- BHLB 4
- ARQT 5
- Target Price
- BHLB $33.13
- ARQT $17.00
- AVG Volume (30 Days)
- BHLB 466.8K
- ARQT 2.1M
- Earning Date
- BHLB 01-30-2025
- ARQT 02-25-2025
- Dividend Yield
- BHLB 2.53%
- ARQT N/A
- EPS Growth
- BHLB N/A
- ARQT N/A
- EPS
- BHLB 0.93
- ARQT N/A
- Revenue
- BHLB $344,859,000.00
- ARQT $138,708,000.00
- Revenue This Year
- BHLB N/A
- ARQT $209.03
- Revenue Next Year
- BHLB $35.09
- ARQT $49.00
- P/E Ratio
- BHLB $30.59
- ARQT N/A
- Revenue Growth
- BHLB N/A
- ARQT 182.84
- 52 Week Low
- BHLB $20.50
- ARQT $3.11
- 52 Week High
- BHLB $32.36
- ARQT $16.20
- Technical
- Relative Strength Index (RSI)
- BHLB 48.77
- ARQT 43.06
- Support Level
- BHLB $27.98
- ARQT $13.10
- Resistance Level
- BHLB $29.26
- ARQT $14.36
- Average True Range (ATR)
- BHLB 0.69
- ARQT 0.99
- MACD
- BHLB 0.10
- ARQT -0.32
- Stochastic Oscillator
- BHLB 69.69
- ARQT 1.95
About BHLB Berkshire Hills Bancorp Inc.
Berkshire Hills Bancorp Inc is a holding company. It provides Commercial Banking, Retail Banking, Consumer Lending, Private Banking and Wealth Management services.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.